Evidence map›Paper›PMID 32103105›Full record

ArticleScientific reports2020

Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer.

Sara Moufarrij, Aneil Srivastava, Stephanie Gomez, Melissa Hadley, Erica Palmer, Paul Tran Austin, Sarah Chisholm, Noor Diab, Kyle Roche, Angela Yu and 5 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 71 papers.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 111 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Role of HDAC6 in carcinomas.Discover oncology · 2026
    Review
  10. Article
  11. Review
  12. Epigenetic regulation in gynecological cancers: a paradigm shift in immunotherapy strategies.Journal of experimental & clinical cancer research : CR · 2025
    Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Sara Moufarrij *The George Washington University Cancer Center, The George Washington University, Washington, DC, USA.
Aneil Srivastava *The George Washington University Cancer Center, The George Washington University, Washington, DC, USA.
Stephanie GomezThe George Washington University Cancer Center, The George Washington University, Washington, DC, USA.
Melissa HadleyThe George Washington University Cancer Center, The George Washington University, Washington, DC, USA.
Erica PalmerThe George Washington University Cancer Center, The George Washington University, Washington, DC, USA.
Paul Tran AustinThe George Washington University Cancer Center, The George Washington University, Washington, DC, USA.ORCID http://orcid.org/0000-0002-3652-6296
Sarah ChisholmThe George Washington University Cancer Center, The George Washington University, Washington, DC, USA.
Noor DiabThe George Washington University Cancer Center, The George Washington University, Washington, DC, USA.
Kyle RocheThe George Washington University Cancer Center, The George Washington University, Washington, DC, USA.
Angela YuThe George Washington University Cancer Center, The George Washington University, Washington, DC, USA.
Jing LiThe George Washington University Cancer Center, The George Washington University, Washington, DC, USA.
Wenge ZhuThe George Washington University Cancer Center, The George Washington University, Washington, DC, USA.
Micael Lopez-AcevedoThe George Washington University Cancer Center, The George Washington University, Washington, DC, USA.
Alejandro VillagraThe George Washington University Cancer Center, The George Washington University, Washington, DC, USA. avillagra@gwu.edu.
Katherine B ChiappinelliThe George Washington University Cancer Center, The George Washington University, Washington, DC, USA. kchiapp1@gwu.edu.
George Washington University · US

Funding

The Role of And-1 in DNA Damage ResponseR01CA177898 · NCI · GEORGE WASHINGTON UNIVERSITY · PI ZHU, WENGE · 2014 to 2018
$1.6M
The Regulation of Cisplatin resistance in ovarian cancerR01CA184717 · NCI · GEORGE WASHINGTON UNIVERSITY · PI ZHU, WENGE · 2014 to 2018
$1.6M
Epigenetic activation of the interferon response to sensitize cancers to immune therapyR00CA204592 · NCI · GEORGE WASHINGTON UNIVERSITY · PI CHIAPPINELLI, KATHERINE B · 2017 to 2019
$747k
NCI NIH HHS R00 CA204592NCI NIH HHS R01 CA177898NCI NIH HHS R01 CA184717
6 · The paper itself

Abstract

Novel therapies are urgently needed for ovarian cancer, the deadliest gynecologic malignancy. Ovarian cancer has thus far been refractory to immunotherapies that stimulate the host immune system to recognize and kill cancer cells. This may be because of a suppressive tumor immune microenvironment and lack of recruitment and activation of immune cells that kill cancer cells. Our previous work showed that epigenetic drugs including DNA methyltransferase inhibitors and histone deacetylase 6 inhibitors (DNMTis and HDAC6is) individually increase immune signaling in cancer cells. We find that combining DNMTi and HDAC6i results in an amplified type I interferon response, leading to increased cytokine and chemokine expression and higher expression of the MHC I antigen presentation complex in human and mouse ovarian cancer cell lines. Treating mice bearing ID8 Trp53-/- ovarian cancer with HDAC6i/DNMTi led to an increase in tumor-killing cells such as IFNg+ CD8, NK, and NKT cells and a reversal of the immunosuppressive tumor microenvironment with a decrease in MDSCs and PD-1

Indexed as

AnimalsB7-H1 AntigenCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesDNA (Cytosine-5-)-MethyltransferasesDrug Resistance, NeoplasmEnzyme InhibitorsFemaleHistone Deacetylase 6Histone Deacetylase InhibitorsHumansInterferon-gammaMiceMice, Inbred C57BLMice, KnockoutNatural Killer T-CellsB7-H1 AntigenCd274 protein, mouseDNA (Cytosine-5-)-MethyltransferasesEnzyme InhibitorsHistone Deacetylase 6Histone Deacetylase InhibitorsInterferon-gamma

Identifiers

PMID32103105
PMCPMC7044433
OpenAlexW3008033956

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.